Flecainide, Tocainide (No longer sold in US)

Cardiovascular Risk

Mortality

  • An excessive mortality or non fatal cardiac arrest rate was observed in patients with non life threatening ventricular arrhythmias who had a recent MI.

Ventricular Pro-arrhythmic

  • Effects have been observed in patients with atrial fibrillation/flutter.
  • This drug is not recommended in patients with chronic atrial fibrillation

Tocaininde Hematological

  • Agrangulocytosis, bone marrow depression, leukopenia, neutropenia, aplastic/hypoplastic anemia and septic shock have been reported when used within therapeutic dose ranges, typically within first 12 wks of therapy.
  • Use with caution in patients with pre-existing marrow failure or cytopenia.

Pulmonary Fibrosis

  • Interstitial pneumonitis, fibrosing alveolitis, pulomnary edema, and pneumonitis have been reported.

Tocainide no longer sold in the United States

Monitoring data

  • Concurrent negative chronotherapy (e.g., digoxin, beta-blockers) may decrease risk
  • Perform CBC with white blood cell, differential, and platelet counts at weekly intervals for first three months of therapy and periodically thereafter.
  • CBC should be performed if patient develops signs of infection.
  • Reports signs of pulmonary symptoms, perform chest x-rays

Package inserts

Flecainide

Additional information

Updated: January 2018